Close Menu

At R&D Directions Insider, Michael Christel speaks with Bert Spilker, who has worked at a variety of drug companies and has written books on drug development, about mergers and acquisitions, clinical trial reform, transparency, and more. "The issue of transparency has been focused on the industry, and during the '90s and early part of this decade, the industry fought this quite strongly," Spilker says, adding that industry's position has changed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.